1
Clinical Trials associated with BVRS-GamVac / Unknown statusPhase 1/2IIT Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac", a Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of
34.5%.
The aim of the study is to assess the safety and immunogenicity of adenoviral-based vaccine against MERS - BVRS-GamVac.
100 Clinical Results associated with BVRS-GamVac
100 Translational Medicine associated with BVRS-GamVac
100 Patents (Medical) associated with BVRS-GamVac
100 Deals associated with BVRS-GamVac